Concepedia

Author

Cathleen Nientiedt

National Center for Tumor DiseasesORCID

Also Known As

C. Nientiedt, C., Nientiedt, Cathleen Nientiedt

21

Publications

421

Citations

10

H-Index

16

Concepts

All Affiliations

National Center for Tumor DiseasesUniversity Hospital HeidelbergHeidelberg UniversityGerman Cancer Research CenterDeutschen Konsortium für Translationale Krebsforschung
CN

About

Cathleen Nientiedt is an author at National Center for Tumor Diseases specializing in pathology, medicine, and urology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

3

3

134

2

Pathology

3

3

134

3

Cancer Genetics

2

2

93

4

Immunology

1

1

51

5

Cancer Cell Biology

1

1

42

Cathleen Nientiedt

×

9

Publications

339

Citations

9

H-Index

YearCitations

Patients Resistant Against PSMA-Targeting α-Radiation Therapy Often Harbor Mutations in DNA Damage-Repair–Associated Genes

Clemens Kratochwil, Frederik L. Giesel, Claus Peter Heußel,

Journal of Nuclear Medicine

2019

81

The BRCA2 mutation status shapes the immune phenotype of prostate cancer

Maximilian Jenzer, Peter Keß, Cathleen Nientiedt,

Cancer Immunology Immunotherapy

2019

51

Mutations in BRCA2 and taxane resistance in prostate cancer

Cathleen Nientiedt, Martina Heller, Volker Endris,

Scientific Reports

2017

42

Overexpression of nuclear AR-V7 protein in primary prostate cancer is an independent negative prognostic marker in men with high-risk disease receiving adjuvant therapy

Xin Chen, Christof Bernemann, Yuri Tolkach,

Urologic Oncology Seminars and Original Investigations

2017

41

Mutations in TP53 or DNA damage repair genes define poor prognostic subgroups in primary prostate cancer

Cathleen Nientiedt, Jan Budczies, Volker Endris,

Urologic Oncology Seminars and Original Investigations

2021

35

Genomic features of renal cell carcinoma with venous tumor thrombus

Gregor Warsow, Daniel Hübschmann, Kortine Kleinheinz,

Scientific Reports

2018

31

Clinical characteristics, treatment outcomes and potential novel therapeutic options for patients with neuroendocrine carcinoma of the prostate

Leonidas Apostolidis, Cathleen Nientiedt, Eva C. Winkler,

Oncotarget

2019

26

High prevalence of DNA damage repair gene defects and TP53 alterations in men with treatment-naïve metastatic prostate cancer –Results from a prospective pilot study using a 37 gene panel

Cathleen Nientiedt, Volker Endris, Maximilian Jenzer,

Urologic Oncology Seminars and Original Investigations

2020

22

Senescent Tumor Cells Are Frequently Present at the Invasion Front: Implications for Improving Disease Control in Patients with Locally Advanced Prostate Cancer

Sebastian Schwarz, Cathleen Nientiedt, Elena‐Sophie Prigge,

Pathobiology

2023

10

Page 1